{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:43:18Z","timestamp":1792460598101,"version":"4.5.0"},"reference-count":198,"publisher":"Impact Journals, LLC","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,6,6]]},"DOI":"10.18632\/oncotarget.16723","type":"journal-article","created":{"date-parts":[[2017,3,31]],"date-time":"2017-03-31T00:16:22Z","timestamp":1490919382000},"page":"38022-38043","source":"Crossref","is-referenced-by-count":2373,"title":["Combination therapy in combating cancer"],"prefix":"10.18632","volume":"8","author":[{"given":"Reza Bayat","family":"Mokhtari","sequence":"first","affiliation":[{"name":"Developmental and Stem Cell Biology, The Hospital for Sick Children, Toronto, Ontario, Canada"},{"name":"Department of Paediatric Laboratory Medicine, The Hospital for Sick Children and Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Immunology and Infectious Diseases, The Forsyth Institute, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina S.","family":"Homayouni","sequence":"additional","affiliation":[{"name":"Developmental and Stem Cell Biology, The Hospital for Sick Children, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narges","family":"Baluch","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine, Queen\u2019s University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeniya","family":"Morgatskaya","sequence":"additional","affiliation":[{"name":"Developmental and Stem Cell Biology, The Hospital for Sick Children, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil","family":"Kumar","sequence":"additional","affiliation":[{"name":"Developmental and Stem Cell Biology, The Hospital for Sick Children, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bikul","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Immunology and Infectious Diseases, The Forsyth Institute, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman","family":"Yeger","sequence":"additional","affiliation":[{"name":"Developmental and Stem Cell Biology, The Hospital for Sick Children, Toronto, Ontario, Canada"},{"name":"Department of Paediatric Laboratory Medicine, The Hospital for Sick Children and Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,3,30]]},"reference":[{"key":"1","unstructured":"Altekruse, Kosary, Krapcho, Neyman, Aminou, Waldron, Ruhl, Howlader, Tatalovich, Cho, Mariotto, Eisner, Lewis, et al. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD. http:\/\/seercancergov\/csr\/1975_2007 based on November 2009 SEER data submission, posted to the SEER web site, 2010."},{"issue":"45","key":"2","first-page":"992","article-title":"Survival of European children and young adults with cancer diagnosed 1995-2002","volume":"2009","author":"Stiller","journal-title":"Eur J Cancer"},{"key":"3","unstructured":"AACR Releases AACR Cancer Progress Report 2015 American Association for Cancer Research. 2015. [Available from: http:\/\/cancerprogressreport.org\/2015\/Pages\/cpr15release.aspx]."},{"issue":"14","key":"4","first-page":"813","article-title":"New approaches to cancer therapy","volume":"2003","author":"Garattini","journal-title":"Ann Oncol"},{"issue":"22","key":"5","first-page":"151","article-title":"The price of innovation: new estimates of drug development costs","volume":"2003","author":"Grabowski","journal-title":"J Health Econ"},{"issue":"7","key":"6","first-page":"178","article-title":"Nutrition and cancer: a summary of the evidence","volume":"1996","author":"Trichopoulos","journal-title":"Cancer Causes Control"},{"issue":"Suppl 2","key":"7","first-page":"SII27","article-title":"Cancer prevention","volume":"349","author":"Lipkin","year":"1997","journal-title":"Lancet"},{"key":"8","unstructured":"Prevention of cancer in the next millennium: Report of the Chemoprevention Working Group to the American Association for Cancer. Research Cancer Res. 1999; 59:4743\u201358."},{"issue":"52","key":"9","first-page":"125","article-title":"Antibody-targeted immunotherapy for treatment of malignancy","volume":"2001","author":"Grillo-Lopez","journal-title":"Annu Rev Med"},{"issue":"31","key":"10","first-page":"1592","article-title":"Development of therapeutic combinations targeting major cancer signaling pathways","volume":"2013","author":"de Bono","journal-title":"J Clin Oncol"},{"issue":"3","key":"11","first-page":"1035","article-title":"Analysis of FDA approved anticancer drugs reveals the future of cancer therapy","volume":"2004","author":"Blagosklonny","journal-title":"Cell Cycle"},{"issue":"30","key":"12","first-page":"135","article-title":"Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer","volume":"2001","author":"Winer","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"16","key":"13","first-page":"263","article-title":"Chemotherapy side effects in pediatric oncology patients: drugs, age, and sex as risk factors","volume":"1988","author":"Zeltzer","journal-title":"Med Pediatr Oncol"},{"issue":"26","key":"14","first-page":"3950","article-title":"Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment","volume":"2008","author":"O\u2019Shaughnessy","journal-title":"J Clin Oncol"},{"issue":"13","key":"15","first-page":"378","article-title":"Combination of carbonic anhydrase inhibitor, acetazolamide, and sulforaphane, reduces the viability and growth of bronchial carcinoid cell lines","volume":"2013","author":"Yeger","journal-title":"BMC Cancer"},{"issue":"26","key":"16","first-page":"77","article-title":"Overcoming limitations of natural anticancer drugs by combining with artificial agents","volume":"2005","author":"Blagosklonny","journal-title":"Trends Pharmacol Sci"},{"issue":"141","key":"17","first-page":"137","article-title":"Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance","volume":"2010","author":"Panyam","journal-title":"J Control Release"},{"issue":"2","key":"18","first-page":"48","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2002","author":"Bates","journal-title":"Nat Rev Cancer"},{"issue":"105","key":"19","first-page":"1045","article-title":"Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice","volume":"2000","author":"Bergsland","journal-title":"J Clin Invest"},{"issue":"59","key":"20","first-page":"3374","article-title":"Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation","volume":"1999","author":"Weichselbaum","journal-title":"Cancer Res"},{"issue":"34","key":"21","first-page":"732","article-title":"Understanding and targeting cancer stem cells: therapeutic implications and challenges","volume":"2013","author":"Chen","journal-title":"Acta Pharmacol Sin"},{"issue":"12","key":"22","first-page":"445","article-title":"Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update","volume":"2015","author":"Ivy","journal-title":"Nat Rev Clin Oncol"},{"issue":"26","key":"23","first-page":"642","article-title":"The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia","volume":"1965","author":"Lee","journal-title":"Blood"},{"issue":"75","key":"24","first-page":"2305","article-title":"Pancreatic Cancer Combination Therapy Using a BH3 Mimetic and a Synthetic Tetracycline","volume":"2015","author":"Fisher","journal-title":"Cancer Res"},{"issue":"7","key":"25","first-page":"1307","article-title":"\u201cTargeting the absence\u201d and therapeutic engineering for cancer therapy","volume":"2008","author":"Blagosklonny","journal-title":"Cell Cycle"},{"issue":"448","key":"26","first-page":"645","article-title":"New uses for old drugs","volume":"2007","author":"Sullivan","journal-title":"Nature"},{"issue":"3","key":"27","first-page":"673","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"2004","author":"Thor","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"28","first-page":"209","article-title":"Simultaneous Targeting of Bladder Tumor Growth, Survival, and Epithelial-to-Mesenchymal Transition with a Novel Therapeutic Combination of Acetazolamide (AZ) and Sulforaphane (SFN)","volume":"2016","author":"Farhat","journal-title":"Target Oncol"},{"issue":"2","key":"29","first-page":"e26961","article-title":"Immunosuppressants in cancer prevention and therapy","volume":"2013","author":"Blagosklonny","journal-title":"Oncoimmunology"},{"issue":"21","key":"30","first-page":"103","article-title":"A new science-business paradigm in anticancer drug development","volume":"2003","author":"Blagosklonny","journal-title":"Trends Biotechnol"},{"issue":"6","key":"31","first-page":"493","article-title":"Tumor dynamics in response to antiangiogenic therapy with oral metronomic topotecan and pazopanib in neuroblastoma xenografts","volume":"2013","author":"Baruchel","journal-title":"Transl Oncol"},{"issue":"47","key":"32","first-page":"89","article-title":"Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway","volume":"2007","author":"Biswal","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"85","key":"33","first-page":"705","article-title":"The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation","volume":"2013","author":"Park","journal-title":"Biochem Pharmacol"},{"issue":"100","key":"34","first-page":"30","article-title":"Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection","volume":"2013","author":"Zhang","journal-title":"Prog Neurobiol"},{"issue":"102","key":"35","first-page":"10070","article-title":"Modifying specific cysteines of the electrophile-sensing human Keap1 protein is insufficient to disrupt binding to the Nrf2 domain Neh2","volume":"2005","author":"Mesecar","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"29","key":"36","first-page":"493","article-title":"The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds","volume":"2009","author":"Yamamoto","journal-title":"Mol Cell Biol"},{"issue":"7","key":"37","first-page":"385","article-title":"Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation","volume":"2005","author":"Yamamoto","journal-title":"Antioxid Redox Signal"},{"issue":"58","key":"38","first-page":"262","article-title":"Dual roles of Nrf2 in cancer","volume":"2008","author":"Zhang","journal-title":"Pharmacol Res"},{"issue":"174","key":"39","first-page":"103","article-title":"Molecular basis for the contribution of the antioxidant responsive element to cancer chemoprevention","volume":"2001","author":"McMahon","journal-title":"Cancer Lett"},{"issue":"555","key":"40","first-page":"133","article-title":"Chemoprevention through the Keap1-Nrf2 signaling pathway by phase 2 enzyme inducers","volume":"2004","author":"Kensler","journal-title":"Mutat Res"},{"issue":"8","key":"41","first-page":"376","article-title":"The antioxidant response element and oxidative stress modifiers in airway diseases","volume":"2008","author":"Reddy","journal-title":"Curr Mol Med"},{"issue":"64","key":"42","first-page":"6424","article-title":"Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis","volume":"2004","author":"Yamamoto","journal-title":"Cancer Res"},{"issue":"372","key":"43","first-page":"65","article-title":"Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL","volume":"2016","author":"Kim","journal-title":"Cancer Lett"},{"issue":"19","key":"44","first-page":"20091","article-title":"The chemistry of curcumin: from extraction to therapeutic agent","volume":"2014","author":"Priyadarsini","journal-title":"Molecules"},{"issue":"2","key":"45","first-page":"22","article-title":"Natural products for cancer prevention associated with Nrf2-ARE pathway","volume":"2","author":"Chen","year":"2013","journal-title":"Food Science and Human Wellness"},{"issue":"10","key":"46","first-page":"e0124000","article-title":"Long term effect of curcumin in restoration of tumour suppressor p53 and phase-II antioxidant enzymes via activation of Nrf2 signalling and modulation of inflammation in prevention of cancer","volume":"2015","author":"Vinayak","journal-title":"PLoS One"},{"issue":"6","key":"47","first-page":"615","article-title":"Antioxidant effects of bioavailability-enhanced curcuminoids in patients with solid tumors: A randomized double-blind placebo-controlled trial","volume":"2014","author":"Sahebkar","journal-title":"Journal of Functional Foods"},{"issue":"29","key":"48","first-page":"15","article-title":"Role of antioxidants in cancer therapy","volume":"2013","author":"Fuchs-Tarlovsky","journal-title":"Nutrition"},{"issue":"33","key":"49","first-page":"407","article-title":"Impact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence from randomized controlled trials","volume":"2007","author":"Gyllenhaal","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"50","first-page":"e0155057","article-title":"A Novel Combinatorial Epigenetic Therapy Using Resveratrol and Pterostilbene for Restoring Estrogen Receptor-alpha (ERalpha) Expression in ERalpha-Negative Breast Cancer Cells","volume":"2016","author":"Tollefsbol","journal-title":"PLoS One"},{"issue":"45","key":"51","first-page":"87","article-title":"[Study on the resveratrol and arsenic trioxide combination induced apoptosis and its mechanism on lung adenocarcinoma cells] [Article in Chinese]","volume":"2016","author":"Zhang","journal-title":"Wei Sheng Yan Jiu"},{"key":"52","doi-asserted-by":"publisher","first-page":"52517","DOI":"10.18632\/oncotarget.9593","article-title":"Dietary phytochemicals and cancer chemoprevention: a review of the clinical evidence","volume":"7","author":"Espinoza","year":"2016","journal-title":"Oncotarget"},{"issue":"24","key":"53","first-page":"987","article-title":"Curcumin and resveratrol induce apoptosis and nuclear translocation and activation of p53 in human neuroblastoma","volume":"2004","author":"Yeger","journal-title":"Anticancer Res"},{"issue":"4","key":"54","first-page":"1419","article-title":"Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics","volume":"2011","author":"Gescher","journal-title":"Cancer Prev Res (Phila)"},{"issue":"10","key":"55","first-page":"1105","article-title":"Squalene selectively protects mouse bone marrow progenitors against cisplatin and carboplatin-induced cytotoxicity in vivo without protecting tumor growth","volume":"2008","author":"Baruchel","journal-title":"Neoplasia"},{"issue":"19","key":"56","first-page":"188","article-title":"Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate","volume":"2011","author":"Herr","journal-title":"Mol Ther"},{"issue":"96","key":"57","first-page":"1170","article-title":"Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma","volume":"2011","author":"McMillin","journal-title":"Haematologica"},{"issue":"67","key":"58","first-page":"1167","article-title":"Sulforaphane potentiates oxaliplatin-induced cell growth inhibition in colorectal cancer cells via induction of different modes of cell death","volume":"2011","author":"Ulrich","journal-title":"Cancer Chemother Pharmacol"},{"issue":"15","key":"59","first-page":"3423","article-title":"Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer","volume":"2009","author":"Yamamoto","journal-title":"Clin Cancer Res"},{"issue":"8","key":"60","first-page":"712","article-title":"Effect of Sulforaphane in Men with Biochemical Recurrence after Radical Prostatectomy","volume":"2015","author":"Mottet","journal-title":"Cancer Prev Res (Phila)"},{"issue":"74","key":"61","first-page":"21","article-title":"Metformin induces microRNA-34a to downregulate the Sirt1\/Pgc-1alpha\/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents","volume":"2014","author":"Jeong","journal-title":"Free Radic Biol Med"},{"issue":"9","key":"62","first-page":"4","article-title":"Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response","volume":"2004","author":"Harrison","journal-title":"Oncologist"},{"issue":"9","key":"63","first-page":"425","article-title":"Hypoxic tumor microenvironment and cancer cell differentiation","volume":"2009","author":"Yun","journal-title":"Curr Mol Med"},{"issue":"75","key":"64","first-page":"199","article-title":"Carbonic anhydrase IX: regulation and role in cancer","volume":"2014","author":"Pastorek","journal-title":"Subcell Biochem"},{"issue":"38","key":"65","first-page":"S65","article-title":"The hypoxic microenvironment: A determinant of cancer stem cell evolution","volume":"2016","author":"Lleonart","journal-title":"Bioessays"},{"issue":"10","key":"66","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd3554","article-title":"Interfering with pH regulation in tumors as a therapeutic strategy","volume":"2011","author":"Neri","journal-title":"Nat Rev Drug Discov"},{"issue":"18","key":"67","first-page":"3100","article-title":"Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy","volume":"2012","author":"Harris","journal-title":"Clin Cancer Res"},{"issue":"96","key":"68","first-page":"104","article-title":"Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer","volume":"2007","author":"Poole","journal-title":"Br J Cancer"},{"issue":"10","key":"69","first-page":"131","article-title":"Identification of an alternatively spliced isoform of carbonic anhydrase XII in diffusely infiltrating astrocytic gliomas","volume":"2008","author":"Parkkila","journal-title":"Neuro Oncol"},{"issue":"577","key":"70","first-page":"439","article-title":"Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH","volume":"2004","author":"Pastorekov\u00e1","journal-title":"FEBS Lett"},{"issue":"21","key":"71","first-page":"3949","article-title":"Hypoxia induced CA9 inhibitory targeting by two different sulfonamide derivatives including acetazolamide in human glioblastoma","volume":"2013","author":"Supuran","journal-title":"Bioorg Med Chem"},{"issue":"92","key":"72","first-page":"423","article-title":"Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model","volume":"2009","author":"Lambin","journal-title":"Radiother Oncol"},{"issue":"2","key":"73","first-page":"340","article-title":"Targeting cancer stem cells: a new therapy to cure cancer patients","volume":"2012","author":"Fu","journal-title":"Am J Cancer Res"},{"issue":"6","key":"74","first-page":"461","article-title":"Stochastic dynamics of hematopoietic tumor stem cells","volume":"2007","author":"Pacheco","journal-title":"Cell Cycle"},{"issue":"124","key":"75","first-page":"1111","article-title":"Stem cells and cancer: two faces of eve","volume":"2006","author":"Fuller","journal-title":"Cell"},{"issue":"32","key":"76","first-page":"5210","article-title":"Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche","volume":"2013","author":"Dedhar","journal-title":"Oncogene"},{"issue":"20","key":"77","first-page":"3467","article-title":"Carbonic anhydrase inhibitors","volume":"2010","author":"Supuran","journal-title":"Bioorg Med Chem Lett"},{"issue":"7","key":"78","first-page":"168","article-title":"Carbonic anhydrases: novel therapeutic applications for inhibitors and activators","volume":"2008","author":"Supuran","journal-title":"Nat Rev Drug Discov"},{"issue":"31","key":"79","first-page":"527","article-title":"The history and rationale of using carbonic anhydrase inhibitors in the treatment of peptic ulcers","volume":"2016","author":"Supuran","journal-title":"In memoriam Ioan Puscas (1932-2015) J Enzyme Inhib Med Chem"},{"issue":"31","key":"80","first-page":"205","article-title":"Synthesis and inhibition potency of novel ureido benzenesulfonamides incorporating GABA as tumor-associated carbonic anhydrase IX and XII inhibitors","volume":"2016","author":"Supuran","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"334","key":"81","first-page":"710","article-title":"Selective inhibition of carbonic anhydrase IX decreases cell proliferation and induces ceramide-mediated apoptosis in human cancer cells","volume":"2010","author":"Puccetti","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"82","first-page":"e10857","article-title":"Molecular targeting of carbonic anhydrase IX in mice with hypoxic HT29 colorectal tumor xenografts","volume":"2010","author":"Smith-Jones","journal-title":"PLoS One"},{"issue":"47","key":"83","first-page":"51","article-title":"Sulforaphane reduces molecular response to hypoxia in ovarian tumor cells independently of their resistance to chemotherapy","volume":"2015","author":"Sedlak","journal-title":"Int J Oncol"},{"issue":"24","key":"84","first-page":"3043","article-title":"Synthesis of 4-(thiazol-2-ylamino)-benzenesulfonamides with carbonic anhydrase I, II and IX inhibitory activity and cytotoxic effects against breast cancer cell lines","volume":"2016","author":"Supuran","journal-title":"Bioorg Med Chem"},{"issue":"9","key":"85","first-page":"e108068","article-title":"Tumor microenvironmental changes induced by the sulfamate carbonic anhydrase IX inhibitor S4 in a laryngeal tumor model","volume":"2014","author":"Kaanders","journal-title":"PLoS One"},{"key":"86","first-page":"1","article-title":"Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells","author":"Fais","year":"2016","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"28","key":"87","first-page":"360","article-title":"Inhibition of carbonic anhydrase activity modifies the toxicity of doxorubicin and melphalan in tumour cells in vitro","volume":"2013","author":"Williams","journal-title":"J Enzyme Inhib Med Chem"},{"key":"88","unstructured":"A Phase I, Multi-center, Open-label, Study to Investigate the Safety, Tolerability and Pharmacokinetic of SLC-0111 in Subjects With Advanced Solid Tumours. [cited August 10, 2016]."},{"key":"89","volume-title":"Molecular Cell Biology","author":"Darnell","year":"2000","edition":"4th ed"},{"key":"90","article-title":"The Tumor Cell Comparative Oncology","author":"Baba","year":"2007","journal-title":"Bucharest The Publishing House of the Romanian Academy"},{"issue":"114","key":"91","first-page":"A160","article-title":"Epigenetics: the science of change","volume":"2006","author":"Weinhold","journal-title":"Environ Health Perspect"},{"issue":"17","key":"92","first-page":"284","article-title":"Epigenetic modulators, modifiers and mediators in cancer aetiology and progression","volume":"2016","author":"Gondor","journal-title":"Nat Rev Genet"},{"issue":"4","key":"93","first-page":"505","article-title":"Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed","volume":"2012","author":"Oyelere","journal-title":"Future Med Chem"},{"issue":"124","key":"94","first-page":"30","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"2014","author":"Johnstone","journal-title":"J Clin Invest"},{"issue":"5","key":"95","first-page":"981","article-title":"Histone deacetylase inhibitors: overview and perspectives","volume":"2007","author":"Marks","journal-title":"Mol Cancer Res"},{"issue":"74","key":"96","first-page":"300","article-title":"Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung","volume":"2011","author":"Ogawa","journal-title":"Lung Cancer"},{"issue":"37","key":"97","first-page":"391","article-title":"Loss of acetylation at lys16 and trimethylation at lys20 of histone h4 is a common hallmark of human cancer","volume":"2005","author":"Calvo","journal-title":"Nat Genet"},{"issue":"28","key":"98","first-page":"1396","article-title":"Chromatin modifiers and the promise of epigenetic therapy in acute leukemia","volume":"2014","author":"Nimer","journal-title":"Leukemia"},{"issue":"2016","key":"99","first-page":"2481865","article-title":"Histone Deacetylase Inhibitors Increase p27(Kip1) by Affecting Its Ubiquitin-Dependent Degradation through Skp2 Downregulation","volume":"2016","author":"Della Ragione","journal-title":"Oxid Med Cell Longev"},{"issue":"6","key":"100","first-page":"21","article-title":"Vorinostat","volume":"2007","author":"Kirkpatrick","journal-title":"Nat Rev Drug Discov"},{"key":"101","unstructured":"Romidepsin U.S. Food and Drug Administration. 2009."},{"key":"102","unstructured":"Panobinostat U.S. Food and Drug Administration (FDA)."},{"issue":"30","key":"103","first-page":"481","article-title":"Phase 1 results from a study of romidepsin in combination with gemcitabine in patients with advanced solid tumors","volume":"2012","author":"Burris","journal-title":"Cancer Invest"},{"issue":"276","key":"104","first-page":"36734","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"2001","author":"Klein","journal-title":"J Biol Chem"},{"issue":"121","key":"105","first-page":"556","article-title":"Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia","volume":"2015","author":"Kantarjian","journal-title":"Cancer"},{"issue":"123","key":"106","first-page":"4027","article-title":"Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients","volume":"2014","author":"Nachbaur","journal-title":"Blood"},{"issue":"71","key":"107","first-page":"115","article-title":"Phase I study of 5-aza-2\u2019-deoxycytidine in combination with valproic acid in non-small-cell lung cancer","volume":"2013","author":"Otterson","journal-title":"Cancer Chemother Pharmacol"},{"issue":"30","key":"108","first-page":"2303","article-title":"Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination","volume":"2012","author":"Lloyd","journal-title":"Invest New Drugs"},{"issue":"23","key":"109","first-page":"3912","article-title":"Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma","volume":"2005","author":"Monga","journal-title":"J Clin Oncol"},{"issue":"109","key":"110","first-page":"2781","article-title":"Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias","volume":"2007","author":"Zwiebel","journal-title":"Blood"},{"issue":"35","key":"111","first-page":"909","article-title":"Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models","volume":"2009","author":"Hess-Stumpp","journal-title":"Int J Oncol"},{"key":"112","article-title":"The role of histone deacetylases (HDACs) in human cancer","volume":"1","author":"Esteller","year":"2007","journal-title":"Mol Oncol"},{"issue":"13","key":"113","first-page":"5411","article-title":"Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies","volume":"2007","author":"Conley","journal-title":"Clin Cancer Res"},{"issue":"17","key":"114","first-page":"156","article-title":"Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma","volume":"2017","author":"Yeger","journal-title":"BMC Cancer"},{"issue":"1","key":"115","first-page":"598","article-title":"Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer","volume":"2011","author":"Delgado","journal-title":"Cancer Discov"},{"issue":"3","key":"116","first-page":"139","article-title":"Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program","volume":"2011","author":"O\u2019Malley","journal-title":"Clin Epidemiol"},{"issue":"155","key":"117","first-page":"152","article-title":"Autocrine growth factors and solid tumor malignancy","volume":"1991","author":"Walker","journal-title":"West J Med"},{"issue":"115","key":"118","first-page":"4934","article-title":"Autoregulatory effects of serotonin on proliferation and signaling pathways in lung and small intestine neuroendocrine tumor cell lines","volume":"2009","author":"Modlin","journal-title":"Cancer"},{"issue":"33","key":"119","first-page":"207","article-title":"Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy","volume":"2012","author":"Semenza","journal-title":"Trends Pharmacol Sci"},{"issue":"223","key":"120","first-page":"268","article-title":"Autocrine growth loop of the epidermal growth factor receptor in normal and immortalized human bronchial epithelial cells","volume":"1996","author":"Viallet","journal-title":"Exp Cell Res"},{"issue":"31","key":"121","first-page":"805","article-title":"Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer","volume":"2014","author":"Bast","journal-title":"Med Oncol"},{"issue":"4","key":"122","first-page":"579","article-title":"Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms","volume":"2004","author":"Kaaks","journal-title":"Nat Rev Cancer"},{"issue":"65","key":"123","first-page":"771","article-title":"Serotonin discovery and stepwise disclosure of 5-HT receptor complexity over four decades Part I. General background and discovery of serotonin as a basis for 5-HT receptor identification","volume":"2013","author":"Gothert","journal-title":"Pharmacol Rep"},{"issue":"92","key":"124","first-page":"179","article-title":"Multiplicity of mechanisms of serotonin receptor signal transduction","volume":"2001","author":"Garnovskaya","journal-title":"Pharmacol Ther"},{"issue":"220","key":"125","first-page":"337","article-title":"Role of serotonin in angiogenesis: induction of angiogenesis by sarpogrelate via endothelial 5-HT1B\/Akt\/eNOS pathway in diabetic mice","volume":"2012","author":"Morishita","journal-title":"Atherosclerosis"},{"issue":"97","key":"126","first-page":"634","article-title":"The effect of serotonin and serotonin antagonists on bladder cancer cell proliferation","volume":"2006","author":"Thompson","journal-title":"BJU Int"},{"issue":"59","key":"127","first-page":"328","article-title":"Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines","volume":"2004","author":"Abrahamsson","journal-title":"Prostate"},{"issue":"343","key":"128","first-page":"1053","article-title":"The 5-HT2A serotoninergic receptor is expressed in the MCF-7 human breast cancer cell line and reveals a mitogenic effect of serotonin","volume":"2006","author":"Vaillancourt","journal-title":"Biochem Biophys Res Commun"},{"issue":"586","key":"129","first-page":"2360","article-title":"Serotonin activates angiogenic phosphorylation signaling in human endothelial cells","volume":"2012","author":"Qu","journal-title":"FEBS Lett"},{"issue":"9","key":"130","first-page":"e112623","article-title":"Immunohistochemical characterization of the chemosensory pulmonary neuroepithelial bodies in the naked mole-rat reveals a unique adaptive phenotype","volume":"2014","author":"Yeger","journal-title":"PLoS One"},{"issue":"860","key":"131","first-page":"309","article-title":"Augmented 5-HT Secretion in Pulmonary Neuroepithelial Bodies from PHD1 Null Mice","volume":"2015","author":"Cutz","journal-title":"Adv Exp Med Biol"},{"issue":"52","key":"132","first-page":"183","article-title":"Carbonic anhydrase II mediates malignant behavior of pulmonary neuroendocrine tumors","volume":"2015","author":"Yeger","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"539","key":"133","first-page":"503","article-title":"Hypoxia-induced secretion of serotonin from intact pulmonary neuroepithelial bodies in neonatal rabbit","volume":"2002","author":"Cutz","journal-title":"J Physiol"},{"issue":"116","key":"134","first-page":"2902","article-title":"The 5-HT(2B) receptor plays a key regulatory role in both neuroendocrine tumor cell proliferation and the modulation of the fibroblast component of the neoplastic microenvironment","volume":"2010","author":"Modlin","journal-title":"Cancer"},{"issue":"3","key":"135","first-page":"164","article-title":"Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target","volume":"2004","author":"Harris","journal-title":"Cell Cycle"},{"issue":"280","key":"136","first-page":"C581","article-title":"Serotonin-elicited inhibition of Cl(-) secretion in the rabbit conjunctival epithelium","volume":"2001","author":"Candia","journal-title":"Am J Physiol Cell Physiol"},{"issue":"68","key":"137","first-page":"5487","article-title":"Serotonin receptors, novel targets of sulforaphane identified by proteomic analysis in Caco-2 cells","volume":"2008","author":"Bao","journal-title":"Cancer Res"},{"issue":"92","key":"138","first-page":"790","article-title":"Carcinoid heart disease Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography","volume":"1995","author":"Feldman","journal-title":"Circulation"},{"issue":"10","key":"139","first-page":"486","article-title":"Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001","volume":"2015","author":"Hosokawa","journal-title":"J Thorac Oncol"},{"issue":"103","key":"140","first-page":"332","article-title":"The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study","volume":"2010","author":"Yin","journal-title":"Br J Cancer"},{"issue":"20","key":"141","first-page":"1925","article-title":"Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer","volume":"2014","author":"Pollak","journal-title":"Clin Cancer Res"},{"issue":"26","key":"142","first-page":"921","article-title":"A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial","volume":"2015","author":"Nemecek","journal-title":"Ann Oncol"},{"issue":"23","key":"143","first-page":"2834","article-title":"A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer","volume":"2012","author":"Hei","journal-title":"Ann Oncol"},{"issue":"15","key":"144","first-page":"267","article-title":"Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01\/UNICANCER)","volume":"2014","author":"Goncalves","journal-title":"Lancet Oncol"},{"issue":"18","key":"145","first-page":"5356","article-title":"New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF","volume":"1999","author":"Yancopoulos","journal-title":"Oncogene"},{"issue":"9","key":"146","first-page":"669","article-title":"The biology of VEGF and its receptors","volume":"2003","author":"LeCouter","journal-title":"Nat Med"},{"issue":"20","key":"147","first-page":"4368","article-title":"Vascular permeability factor\/ vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy","volume":"2002","author":"Dvorak","journal-title":"J Clin Oncol"},{"issue":"31","key":"148","first-page":"104","article-title":"Upregulation of VEGF-A and CD24 gene expression by the tGLI1 transcription factor contributes to the aggressive behavior of breast cancer cells","volume":"2012","author":"Lo","journal-title":"Oncogene"},{"issue":"73","key":"149","first-page":"1097","article-title":"Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis","volume":"2013","author":"Detmar","journal-title":"Cancer Res"},{"issue":"299","key":"150","first-page":"741","article-title":"Integrin alpha4 Induces Lymphangiogenesis and Metastasis via Upregulation of VEGF-C in Human Colon Cancer","volume":"2016","author":"Zhang","journal-title":"Anat Rec (Hoboken)"},{"issue":"50","key":"151","first-page":"58","article-title":"UVB-irradiation regulates VLA-4-mediated melanoma cell adhesion to endothelial VCAM-1 under flow conditions","volume":"2011","author":"Wu","journal-title":"Mol Carcinog"},{"issue":"60","key":"152","first-page":"203","article-title":"Regulation of angiogenesis via vascular endothelial growth factor receptors","volume":"2000","author":"Alitalo","journal-title":"Cancer Res"},{"issue":"5","key":"153","first-page":"186","article-title":"Metronomic chemotherapy","volume":"2014","author":"Maiti","journal-title":"J Pharmacol Pharmacother"},{"issue":"4","key":"154","first-page":"423","article-title":"The anti-angiogenic basis of metronomic chemotherapy","volume":"2004","author":"Kamen","journal-title":"Nat Rev Cancer"},{"issue":"22","key":"155","first-page":"3361","article-title":"VEGF receptor expression and signaling in human bladder tumors","volume":"2003","author":"Broek","journal-title":"Oncogene"},{"key":"156","article-title":"Refractory angiosarcoma of the breast with VEGFR2 upregulation successfully treated with sunitinib","volume":"21","author":"Voss","year":"2015","journal-title":"Breast J"},{"issue":"71","key":"157","first-page":"6764","article-title":"Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer","volume":"2011","author":"Rudin","journal-title":"Cancer Res"},{"issue":"8","key":"158","first-page":"619","article-title":"Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer","volume":"2013","author":"Liu","journal-title":"J Thorac Oncol"},{"issue":"35","key":"159","first-page":"4191","article-title":"Combination Chemotherapy with Itraconazole for Treating Metastatic Pancreatic Cancer in the Second-line or Additional Setting","volume":"2015","author":"Yamanaka","journal-title":"Anticancer Res"},{"issue":"111","key":"160","first-page":"43","article-title":"Combined therapy using bevacizumab and turmeric ethanolic extract (with absorbable curcumin) exhibited beneficial efficacy in colon cancer mice","volume":"2016","author":"Lau","journal-title":"Pharmacol Res"},{"issue":"15","key":"161","first-page":"1236","article-title":"Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study","volume":"2014","author":"Yamanaka","journal-title":"Lancet Oncol"},{"issue":"74","key":"162","first-page":"368","article-title":"Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality","volume":"2015","author":"Harris","journal-title":"EMBO Mol Med"},{"issue":"48","key":"163","first-page":"39","article-title":"HIF-1alpha activation mediates resistance to anti-angiogenic therapy in neuroblastoma xenografts","volume":"2013","author":"Davidoff","journal-title":"J Pediatr Surg"},{"issue":"4","key":"164","first-page":"1307","article-title":"How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy","volume":"2005","author":"Blagosklonny","journal-title":"Cancer Biol Ther"},{"issue":"25","key":"165","first-page":"4798","article-title":"Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy","volume":"2006","author":"Debatin","journal-title":"Oncogene"},{"issue":"35","key":"166","first-page":"495","article-title":"Apoptosis: a review of programmed cell death","volume":"2007","author":"Elmore","journal-title":"Toxicol Pathol"},{"issue":"11","key":"167","first-page":"1833","article-title":"Deficient activation of the CD95 (APO-1\/Fas) system in drug-resistant cells","volume":"1997","author":"Debatin","journal-title":"Leukemia"},{"issue":"31","key":"168","first-page":"18","article-title":"Unraveling biologic therapy for Bcl-2-expressing malignancies","volume":"2004","author":"Cotter","journal-title":"Semin Oncol"},{"issue":"10","key":"169","first-page":"186","article-title":"High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology","volume":"2010","author":"Homer","journal-title":"BMC Cancer"},{"issue":"10","key":"170","first-page":"7662","article-title":"Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer","volume":"2004","author":"Bally","journal-title":"Clin Cancer Res"},{"issue":"143","key":"171","first-page":"1543","article-title":"Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification","volume":"1993","author":"Nunez","journal-title":"Am J Pathol"},{"issue":"55","key":"172","first-page":"4438","article-title":"Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo","volume":"1995","author":"Buttyan","journal-title":"Cancer Res"},{"issue":"9","key":"173","first-page":"1","article-title":"Efficacy and safety of nitroglycerin combined with chemotherapy in the elderly patients with advanced non-small cell lung cancer complicated with coronary heart disease","volume":"2016","author":"Wu","journal-title":"J Clin Exp Med"},{"issue":"142","key":"174","first-page":"296","article-title":"Nitroglycerin enhances vascular blood flow and drug delivery in hypoxic tumor tissues: analogy between angina pectoris and solid tumors and enhancement of the EPR effect","volume":"2010","author":"Maeda","journal-title":"J Control Release"},{"issue":"24","key":"175","first-page":"688","article-title":"Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB\/IV non-small-cell lung cancer","volume":"2006","author":"Kaneta","journal-title":"J Clin Oncol"},{"issue":"46","key":"176","first-page":"863","article-title":"New macrolide antibiotics: clarithromycin and azithromycin","volume":"1992","author":"Stott","journal-title":"Am Fam Physician"},{"issue":"42","key":"177","first-page":"1541","article-title":"Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells","volume":"2013","author":"Miyazawa","journal-title":"Int J Oncol"},{"issue":"40","key":"178","first-page":"1029","article-title":"Clarithromycin enhances bortezomib-induced cytotoxicity via endoplasmic reticulum stress-mediated CHOP (GADD153) induction and autophagy in breast cancer cells","volume":"2012","author":"Tomoda","journal-title":"Int J Oncol"},{"issue":"437","key":"179","first-page":"41","article-title":"Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells","volume":"2013","author":"Miyazawa","journal-title":"Biochem Biophys Res Commun"},{"key":"180","article-title":"A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas","author":"Fine","year":"2015","journal-title":"J Neurooncol"},{"issue":"10","key":"181","first-page":"158","article-title":"Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancer","volume":"2015","author":"Verheij","journal-title":"Radiat Oncol"},{"issue":"15","key":"182","first-page":"443","article-title":"Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study","volume":"2015","author":"Zanna","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"24","key":"183","first-page":"1777","article-title":"A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer","volume":"2013","author":"Galimi","journal-title":"Ann Oncol"},{"issue":"12","key":"184","first-page":"34","article-title":"Multi-target therapeutics: when the whole is greater than the sum of the parts","volume":"2007","author":"Keith","journal-title":"Drug Discov Today"},{"issue":"15","key":"185","first-page":"2","article-title":"p53 mutations in cancer","volume":"2013","author":"Vousden","journal-title":"Nat Cell Biol"},{"issue":"75","key":"186","first-page":"196","article-title":"Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells","volume":"2009","author":"Heasley","journal-title":"Mol Pharmacol"},{"issue":"31","key":"187","first-page":"2283","article-title":"Non-canonical HIF-2alpha function drives autonomous breast cancer cell growth via an AREG-EGFR\/ErbB4 autocrine loop","volume":"2012","author":"Wenger","journal-title":"Oncogene"},{"issue":"17","key":"188","first-page":"165","article-title":"Overexpression of VEGF-C correlates with a poor prognosis in esophageal cancer patients","volume":"2016","author":"Ma","journal-title":"Cancer Biomark"},{"issue":"6","key":"189","first-page":"155","article-title":"Hypoxia induces VEGF-C expression in metastatic tumor cells via a HIF-1alpha-independent translation-mediated mechanism","volume":"2014","author":"Pyronnet","journal-title":"Cell Rep"},{"issue":"17","key":"190","first-page":"1044","article-title":"Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy","volume":"2012","author":"Sahoo","journal-title":"Drug Discov Today"},{"issue":"292","key":"191","first-page":"470","article-title":"Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis","volume":"2004","author":"Pignon","journal-title":"JAMA"},{"issue":"17","key":"192","first-page":"698","article-title":"Combination therapy targeting both cancer stem-like cells and bulk tumor cells for improved efficacy of breast cancer treatment","volume":"2016","author":"Torchilin","journal-title":"Cancer Biol Ther"},{"issue":"31","key":"193","first-page":"23","article-title":"Effective elimination of cancer stem cells by a novel drug combination strategy","volume":"2013","author":"Huang","journal-title":"Stem Cells"},{"issue":"26","key":"194","first-page":"2839","article-title":"Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis","volume":"2008","author":"Rich","journal-title":"J Clin Oncol"},{"issue":"100","key":"195","first-page":"670","article-title":"Phase I\/II study of the combination of panobinostat and carfilzomib in patients with relapsed\/refractory multiple myeloma","volume":"2015","author":"Flinn","journal-title":"Haematologica"},{"issue":"99","key":"196","first-page":"592","article-title":"Potential drug interactions and duplicate prescriptions among cancer patients","volume":"2007","author":"Krzyzanowska","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"197","first-page":"1063","article-title":"A mutated soluble neuropilin-2 B domain antagonizes vascular endothelial growth factor bioactivity and inhibits tumor progression","volume":"2010","author":"Klagsbrun","journal-title":"Mol Cancer Res"},{"issue":"61","key":"198","first-page":"5736","article-title":"Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells","volume":"2001","author":"Mercurio","journal-title":"Cancer Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.16723","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T15:34:18Z","timestamp":1589124858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.16723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,30]]},"references-count":198,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2017,6,6]]}},"alternative-id":["16723","28410237"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.16723","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,30]]}}}